Publisher： Karger
E-ISSN： 1423-0194|82|3-4|171-176
ISSN： 0028-3835
Source： Neuroendocrinology, Vol.82, Iss.3-4, 2006-05, pp. : 171-176
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
CHS 828, a cyanoguanidine with potent experimental antitumoural activity, inhibits activation of nuclear factor-ĸB. In the present study, marked antitumoural activity of peroral CHS 828 was shown against three different human neuroendocrine tumours, midgut carcinoid (GOT1), pancreatic carcinoid (BON), and medullary thyroid carcinoma (GOT2), transplanted in nude mice. Our results indicate that CHS 828 can be a candidate drug for treatment of neuroendocrine tumours.
Related content
Changes in the Epidemiology of Neuroendocrine Tumours
Neuroendocrinology, Vol. 104, Iss. 2, 2015-10 ,pp. :
Access to resources
Recommend
Epidemiology of Neuroendocrine Tumours
Neuroendocrinology, Vol. 80, Iss. 1, 2004-10 ,pp. :
Tumour Biology of Gastroenteropancreatic Neuroendocrine Tumours
Neuroendocrinology, Vol. 80, Iss. 1, 2004-10 ,pp. :
Guidelines for the Diagnosis and Treatment of Neuroendocrine Gastrointestinal Tumours
Neuroendocrinology, Vol. 80, Iss. 6, 2005-05 ,pp. :
Quality of Clinical Trials in Gastroenteropancreatic Neuroendocrine Tumours
Neuroendocrinology, Vol. 96, Iss. 3, 2012-08 ,pp. :